CN1304732A - Chinese patent medicine for treating hyperosteogeny - Google Patents

Chinese patent medicine for treating hyperosteogeny Download PDF

Info

Publication number
CN1304732A
CN1304732A CN00112932A CN00112932A CN1304732A CN 1304732 A CN1304732 A CN 1304732A CN 00112932 A CN00112932 A CN 00112932A CN 00112932 A CN00112932 A CN 00112932A CN 1304732 A CN1304732 A CN 1304732A
Authority
CN
China
Prior art keywords
parts
rhizoma
radix
chinese patent
hyperosteogeny
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00112932A
Other languages
Chinese (zh)
Other versions
CN1150012C (en
Inventor
陈纬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luo Jinxiu
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB001129325A priority Critical patent/CN1150012C/en
Publication of CN1304732A publication Critical patent/CN1304732A/en
Application granted granted Critical
Publication of CN1150012C publication Critical patent/CN1150012C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A Chinese patent medicine in the form of capsule, tablet, or decoction for treating osteoporosis and hyperosteogeny is prepared from 15 Chinese-medicinal materials including Chuan-xiong rhizome, oyster shell, lucid ligustrum fruit, rehmannia root, white peony root, etc. It has high curative effect.

Description

The Chinese patent medicine of treatment hyperosteogeny
The present invention relates to a kind of is the Chinese patent medicine of raw material for treating hyperosteogeny with the Chinese crude drug, also applicable to the treatment cataract.
Clinical practice and the theory study of inventor through being engaged in hyperosteogeny disease for a long time, find that the main cause that hyperosteogeny disease produces is the functional trace element imbalance of human body integral, and the weak curative effect of the Chinese patent medicine of existing treatment hyperosteogeny, the one, because can not effectively replenish the various trace element of necessary for human body, as zinc, calcium, chromium, copper, ferrum, molybdenum etc., the 2nd, can not strengthen the physiological metabolism function.
Purpose of the present invention is intended to overcome above-mentioned the deficiencies in the prior art, the inventor is through studying intensively theory of Chinese medical science with great concentration and by a large amount of clinical practices, proposed the preparation method that a kind of cost is low, processor simply can effectively be treated Chinese patent medicine and this Chinese patent medicine of hyperosteogeny decades.
Above-mentioned Chinese patent medicine has another name called controls the bone spirit that makes eye bright.
The technical scheme that realizes above-mentioned purpose be a kind of be raw material with the Chinese crude drug, the Chinese patent medicine of the treatment hyperosteogeny that after scientific ingredients processing, makes, dosage form is a capsule, tablet or water preparation, it is by Concha Ostreae, Fructus Ligustri Lucidi, Rhizoma Chuanxiong, the Radix Rehmanniae, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Ramulus Cinnamomi, the Cortex Eucommiae, Radix Puerariae, Radix Ophiopogonis, the Rhizoma Anemarrhenae, Fructus Lycii and Rhizoma Coptidis ten Chinese medicine of the five flavours raw materials are formed, and its raw material umber by weight ratio is 20~30 parts of Concha Ostreaes, 10~20 parts of Fructus Ligustri Lucidis, 15~25 parts of Rhizoma Chuanxiongs, 15~25 parts in the Radix Rehmanniae, 10~20 parts of the Rhizoma Atractylodis Macrocephalaes, 10~20 parts in Poria, 2~10 parts of Polyporus, 2~10 parts of Rhizoma Alismatis, 10~15 parts of Ramulus Cinnamomi, 10~20 parts of the Cortexs Eucommiae, 10~20 parts of Radix Puerariaes, 10~20 parts of Radix Ophiopogonis, 3~4 parts of the Rhizoma Anemarrhenaes, 2~10 parts of Fructus Lyciis, 1 part of Rhizoma Coptidis.
The Chinese patent medicine of above-mentioned treatment hyperosteogeny, its raw material of Chinese medicine umber by weight ratio are 30 parts of Concha Ostreaes, 20 parts of Fructus Ligustri Lucidis, 20 parts of Rhizoma Chuanxiongs, 20 parts in the Radix Rehmanniae, 20 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts in Poria, 5 parts of Polyporus, 5 parts of Rhizoma Alismatis, 15 parts of Ramulus Cinnamomi, 15 parts of the Cortexs Eucommiae, 10 parts of Radix Puerariaes, 10 parts of Radix Ophiopogonis, 4 parts of the Rhizoma Anemarrhenaes, 10 parts of Fructus Lyciis, 1 part of Rhizoma Coptidis.
Also include vitamin C, compound vitamin B in the above-mentioned raw materials.
Preparation method of the present invention comprises batching, washes, dries, dry, pulverize, sieve and encapsulated, making step is as follows:
A, batching are weight proportion weighings by above-mentioned raw materials, the Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii cleaned and dry, and in 60~70 ℃ of dryings 6~8 hours,
B, batching are by above-mentioned weight proportion weighing, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Ramulus Cinnamomi, Fructus Ligustri Lucidi, Rhizoma Chuanxiong, Radix Puerariae, the Rhizoma Anemarrhenae, the Cortex Eucommiae, Rhizoma Coptidis, Concha Ostreae cleaned dried, and in 60~70 ℃ of dryings 2~3 hours,
C, will mix through the Chinese medicine of step a, b and pulverize, cross 80~100 mesh sieves,
D, will pack in the 0.5g capsule through the fine powder of step c.
In above-mentioned steps c, also can add vitamin C, compound vitamin B and pulverizing after the Chinese medicine of step a, b is mixed together.
The ten Chinese medicine of the five flavours raw materials that the present invention is selected, all contain abundant trace element, particularly Concha Ostreae, Rhizoma Chuanxiong, Fructus Ligustri Lucidi and the Radix Rehmanniae separately, wherein: Concha Ostreae is rich in ferrum, manganese, nickel, copper, strengthen three major nutrient (sugar, protein and fat) metabolism, eliminate free radical in the blood; The zinc of Rhizoma Chuanxiong, ferrum, copper are beneficial to blood circulation promoting and blood stasis dispelling, eliminate free radical, help to strengthen the metabolism of three major nutrient; Fructus Ligustri Lucidi is rich in molybdenum, ferrum, nickel, zinc, chromium, blood fat reducing, cholesterol reducing, blood sugar lowering, enhancing body metabolic function; The Radix Rehmanniae is rich in zinc, chromium, strontium, promotes various physiological metabolism functions in the body, gets rid of refuse, blood fat reducing, blood sugar lowering, falls blood uric acid etc.According to the Chinese patent medicine that the consumption proportion of the present invention and the preparation method that adopts make, trace element such as necessary for human body such as zinc, calcium, chromium, molybdenum, ferrum, molybdenum are abundant, and the existence form of trace element is easy to absorption of human body.Through a large amount of clinical practices, the present invention has kidney tonifying and invigorates blood circulation, and strengthens the liver metabolism function, promotes the protein synthesis enzyme, and bone strengthening makes eye bright, and is evident in efficacy.In addition, the present invention all has preferably curative effect to coronary heart disease, hypertension, diabetes, gout and complication etc., and (its clinical data and pathology are inquired into and are seen Appendix 1~8, and these adnexaes are for the original bill application number is 97107839.4, the applying date is the adnexa that 97.12.24, denomination of invention provide in the statement to the examination reports first time for " effectively treating the Chinese patent medicine of senile disease ".)。
The present invention is further detailed explanation below by embodiment:
Embodiment one: a kind of Chinese patent medicine for the treatment of hyperosteogeny, its proportioning raw materials be Rhizoma Atractylodis Macrocephalae 2000g, Poria 1500g, Polyporus 500g, Rhizoma Alismatis 500g, Ramulus Cinnamomi 1500g, Rhizoma Chuanxiong 2000g, Concha Ostreae 3000g, Cortex Eucommiae 1500g, Fructus Ligustri Lucidi 2000g, Radix Puerariae 1000g, Radix Rehmanniae 2000g, Radix Ophiopogonis 1000g, Rhizoma Anemarrhenae 400g, Fructus Lycii 1000g and Rhizoma Coptidis 100g.
The preparation method of above-mentioned Chinese patent medicine:
1, a Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii were cleaned and to dry, in 60~70 ℃ of dryings 6~8 hours.
The b Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Ramulus Cinnamomi, Fructus Ligustri Lucidi, Rhizoma Chuanxiong, Radix Puerariae, the Rhizoma Anemarrhenae, the Cortex Eucommiae, Rhizoma Coptidis, Concha Ostreae were cleaned and are dried, in 60~70 ℃ of dryings 2~3 hours.
2, a in the above-mentioned steps 1 and b are mixed the back pulverizing, cross 80~100 mesh sieves;
3, step 2 gained fine powder is packed in the 0.5g capsule.
Also can mix and add vitamin C 60g before pulverizing at above-mentioned four Chinese medicine material, the compound rope B9.42g effect of supporting one's family is better.
Present embodiment Chinese patent medicine characteristics: kidney tonifying is invigorated blood circulation, and strengthens the liver metabolism function, promotes the protein synthesis enzyme, and bone strengthening makes eye bright, and is evident in efficacy.
Embodiment two: a kind of Chinese patent medicine for the treatment of hyperosteogeny, its raw material be by weight ratio Rhizoma Atractylodis Macrocephalae 2000g, Poria 1500g, Polyporus 1000g, Rhizoma Alismatis 1000g, Ramulus Cinnamomi 1000g, Rhizoma Chuanxiong 2000g, Concha Ostreae 2000g, Cortex Eucommiae 1500g, Fructus Ligustri Lucidi 2000g, Radix Puerariae 1000g, Radix Rehmanniae 2000g, Radix Ophiopogonis 1500g, Rhizoma Anemarrhenae 400g, Fructus Lycii 1000g and Rhizoma Coptidis 100g.
The preparation method of present embodiment proportioning raw materials Chinese patent medicine is with embodiment one.
Make the Chinese patent medicine characteristics according to present embodiment: have kidney tonifying and invigorate blood circulation, strengthen the metabolism of each histoorgan in the body, be suitable for middle-aged and elderly people, osteoporosis, hyperosteogeny and the deformation of moving back property due to physiological function suddenly moves back.
Embodiment three: a kind of Chinese patent medicine for the treatment of hyperosteogeny, its proportioning raw materials be Rhizoma Atractylodis Macrocephalae 1000g, Poria 1000g, Polyporus 200g, Rhizoma Alismatis 200g, Ramulus Cinnamomi 1200g, Rhizoma Chuanxiong 2500g, Concha Ostreae 1500g, Cortex Eucommiae 1000g, Fructus Ligustri Lucidi 1500g, Radix Puerariae 2000g, Radix Rehmanniae 2500g, Radix Ophiopogonis 2000g, Rhizoma Anemarrhenae 200g, Fructus Lycii 200g and Rhizoma Coptidis 100g.
The preparation method of present embodiment proportioning raw materials Chinese patent medicine is with embodiment one.
Make the Chinese patent medicine characteristics according to present embodiment: have human activin endoenzyme metabolic activity, control agent intracellular metabolite function has blood sugar lowering, blood uric acid, blood fat, is applicable to moving back property of the element imbalance sclerotin deformation due to the metabolic disease.
Chinese patent medicine also can be water preparation except that adopting above-mentioned capsule form, it is to be soaked in water about half an hour after a in the above-mentioned steps 1, b are mixed, and through the filtration of removing slag, extracts medicinal liquid half an hour after the heating of reuse temperature fire is boiled, and bottling gets product.
Chinese patent medicine also can be tablet, and its preparation method is a prior art.
In the foregoing description two and three, also can add appropriate vitamin C and compound vitamin B as required, this moment, the preparation method of Chinese patent medicine only needed in step 2 vitamin C and compound vitamin B are mixed pulverizing afterwards with a, b in the step 1, crossing 80~100 mesh sieves gets final product, other preparation methoies are identical, get vitamin C 60g here, compound vitamin B 9.42g is advisable.
When taking this Chinese medicine capsule, day clothes three times are looked 4~8 of its state of an illness weight clothes at every turn.
In sum, clinical therapeutic efficacy of the present invention is good, and needed raw material is easy to get, and cost is low, and processing technology is simple, and the condition of practicing midwifery is not high, is well suited for the pharmaceutical factory with the encapsulated production line of automatization and practices midwifery.

Claims (5)

1, a kind of Chinese patent medicine for the treatment of hyperosteogeny, it is characterized in that: it is by Concha Ostreae, Fructus Ligustri Lucidi, Rhizoma Chuanxiong, the Radix Rehmanniae, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Ramulus Cinnamomi, the Cortex Eucommiae, Radix Puerariae, Radix Ophiopogonis, the Rhizoma Anemarrhenae, Fructus Lycii and Rhizoma Coptidis ten Chinese medicine of the five flavours raw materials are formed, and its raw material umber by weight ratio is 20~30 parts of Concha Ostreaes, 10~20 parts of Fructus Ligustri Lucidis, 15~25 parts of Rhizoma Chuanxiongs, 15~25 parts in the Radix Rehmanniae, 10~20 parts of the Rhizoma Atractylodis Macrocephalaes, 10~20 parts in Poria, 2~10 parts of Polyporus, 2~10 parts of Rhizoma Alismatis, 10~15 parts of Ramulus Cinnamomi, 10~20 parts of the Cortexs Eucommiae, 10~20 parts of Radix Puerariaes, 10~20 parts of Radix Ophiopogonis, 3~4 parts of the Rhizoma Anemarrhenaes, 2~10 parts of Fructus Lyciis, 1 part of Rhizoma Coptidis.
2, according to the described a kind of Chinese patent medicine for the treatment of hyperosteogeny of claim 1, it is characterized in that: raw material umber by weight ratio is 30 parts of Concha Ostreaes, 20 parts of Fructus Ligustri Lucidis, 20 parts of Rhizoma Chuanxiongs, 20 parts in the Radix Rehmanniae, 20 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts in Poria, 5 parts of Polyporus, 5 parts of Rhizoma Alismatis, 15 parts of Ramulus Cinnamomi, 15 parts of the Cortexs Eucommiae, 10 parts of Radix Puerariaes, 10 parts of Radix Ophiopogonis, 4 parts of the Rhizoma Anemarrhenaes, 10 parts of Fructus Lyciis, 1 part of Rhizoma Coptidis.
3, according to claim 1 or 2 described a kind of Chinese patent medicines for the treatment of hyperosteogeny, it is characterized in that: also include vitamin C, compound vitamin B in the batching.
4, a kind of is raw material with the Chinese crude drug, processes from strand to make the Chinese patent medicine of treatment hyperosteogeny, it is characterized in that: preparation method comprises batching, washes, dries, drying, pulverize, sieve, encapsulated getting product, making step is as follows:
A, batching are by the described weight proportion weighing of claim 1, the Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii cleaned dried, and in 60~70 ℃ of dryings 6~8 hours,
B, batching are by the described weight proportion weighing of claim 1, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Ramulus Cinnamomi, Fructus Ligustri Lucidi, Rhizoma Chuanxiong, Radix Puerariae, the Rhizoma Anemarrhenae, the Cortex Eucommiae, Rhizoma Coptidis, Du oyster cleaned dried, and in 60~70 ℃ of dryings 2~3 hours,
C, will mix through the Chinese medicine of step a, b and pulverize, cross 80~100 mesh sieves,
D, the fine powder of step c is packed in the 0.5g capsule.
5, according to the Chinese patent medicine of the described treatment hyperosteogeny of claim 4, it is characterized in that: in step c, vitamin C, compound vitamin B and pulverizing after the Chinese medicine of step a, b is mixed together.
CNB001129325A 2000-05-15 2000-05-15 Chinese patent medicine for treating hyperosteogeny Expired - Fee Related CN1150012C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB001129325A CN1150012C (en) 2000-05-15 2000-05-15 Chinese patent medicine for treating hyperosteogeny

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB001129325A CN1150012C (en) 2000-05-15 2000-05-15 Chinese patent medicine for treating hyperosteogeny

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN97107839A Division CN1060074C (en) 1997-12-24 1997-12-24 Chinese patent drug for treating effevctively old and feeble type disease

Publications (2)

Publication Number Publication Date
CN1304732A true CN1304732A (en) 2001-07-25
CN1150012C CN1150012C (en) 2004-05-19

Family

ID=4582754

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB001129325A Expired - Fee Related CN1150012C (en) 2000-05-15 2000-05-15 Chinese patent medicine for treating hyperosteogeny

Country Status (1)

Country Link
CN (1) CN1150012C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102389440A (en) * 2011-12-09 2012-03-28 四川浩源生物科技有限公司 Application of iridoid in preparation of anti-osteoporosis medicines
CN107519477A (en) * 2017-06-26 2017-12-29 郑相国 Chinese patent drug with healthcare function

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102389440A (en) * 2011-12-09 2012-03-28 四川浩源生物科技有限公司 Application of iridoid in preparation of anti-osteoporosis medicines
CN102389440B (en) * 2011-12-09 2014-08-20 四川浩源生物科技有限公司 Application of iridoid in preparation of anti-osteoporosis medicines
CN107519477A (en) * 2017-06-26 2017-12-29 郑相国 Chinese patent drug with healthcare function

Also Published As

Publication number Publication date
CN1150012C (en) 2004-05-19

Similar Documents

Publication Publication Date Title
CN1437959A (en) Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method
CN1027622C (en) A tonic and health protecting preparation
CN1287848C (en) Kidney failure resistant formula and its preparation process
CN1228327A (en) Traditional Chinese medicine for curing gastrointestinal disease
CN1857572A (en) Hypolipidemic health article and its preparing method
CN1150012C (en) Chinese patent medicine for treating hyperosteogeny
CN1114425C (en) Chinese patent medicine for treating coronary heart disease and hypertension
CN1079029C (en) Medical capsule for treating bone rheumatism and preparing process
CN1143516A (en) Balanced nutritious food-kangfusu and preparing process thereof
CN1105557A (en) Method for preparation of weight-loosing medicine and its products
CN106666733A (en) Nourishing paste with functions of producing blood, tonifying kidney, blacking hair and strengthening physique
CN1270758C (en) Chinese medicinal preparation for treating cerebral apoplexy
CN1268353C (en) Traditional Chinese medicine preparation for treating amblyopia and method for preparing the same
CN1175884C (en) Kidney-reinforcing Yang-invigorating pill for treating sexual impotence, and preparing process thereof
CN102125645A (en) Traditional Chinese medicine preparation for treating osteoporosis
CN1022165C (en) Preparation and process of oral medicinal liquid for recuperating blood vessels
CN1060074C (en) Chinese patent drug for treating effevctively old and feeble type disease
CN1650990A (en) Chinese medicine for treating diabetes
CN1212149C (en) Cinese material medical preparation for curing children' hyperkinetic symptom and the preparation process thereof
CN1836718A (en) Health traditional Chinese medicine for invigorating constitution, strengthening brain and activating blood
CN100413521C (en) Health product for reducing blood fat, and preparation method
CN1124851C (en) Chinese patent medicine (Tangshenkang) for treating diabetes and nephrosis and its preparing process
CN1079251C (en) Medicine for treating diseases of central nervous system and its prodn. method
CN103340402B (en) Cream of peanuts, red dates and edible fungus, and preparation method and application of cream
CN1306928C (en) Chinese traditional medicine for treating laryngopharyngeal paresthesia and its preparation

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: LUO JINXIU

Free format text: FORMER OWNER: CHEN WEI

Effective date: 20060728

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20060728

Address after: 618000 Deyang Institute of sexology, No. 219 Tianshan Road, Sichuan, Deyang

Patentee after: Luo Jinxiu

Address before: 618000 Huashan North Road East electric hospital, Deyang, Sichuan

Patentee before: Chen Wei

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040519

Termination date: 20100125